NEWS
Go back
ARCHIMED finalizes the acquisition of IBA Lifesciences GmbH by Cube Biotech
January
13,
2025
ARCHIMED finalizes the acquisition of IBA Lifesciences GmbH by Cube Biotech
The acquisition represents a transformational transaction for Cube, bringing critical size, complementing Cube’s protein purification portfolio, reinforcing its market position and boosting its profitability.
Based in Germany, IBA Lifesciences GmbH is a life science tools company that offers reagents for protein purification and characterization based on its proprietary Strep-Tag® affinity technology. Products based on IBA’s technology platform are used for a range of research applications including protein purification. IBA is a longstanding customer of Cube Biotech GmbH for protein purification reagents (Magnetic Beads), which are compatible with IBA’s technology platform.
This strategic acquisition highlights Cube Biotech’s vision to accelerate innovation, streamline services, and expand global outreach, following several key partnerships already concluded in the past 12 months.
By combining its expertise in protein technologies with IBA Lifesciences’ robust research tools for protein isolation, Cube is uniquely positioned to address the evolving needs of researchers and industry professionals worldwide. The new entity will provide a full range offering in all significant affinity-tag purification technologies, driving further innovation in biotechnology and reinforcing Cube’s pioneering positioning in membrane protein production and purification technologies.
Didier Dargent, CEO of Cube Biotech, stated, “This acquisition opens an exciting new chapter for both companies. Together, we will harness our collective expertise to push the boundaries of what’s possible in Life Sciences and enable researchers to make groundbreaking discoveries.”
Dr. Mike Rothe, CEO of IBA Lifesciences, added, “Merging our technologies and talents provides a strong foundation for innovation, ultimately benefiting our customers and enhancing our leadership in the biotechnology sector.”
“Together, we will harness our collective expertise to push the boundaries of what’s possible in Life Sciences and enable researchers to make groundbreaking discoveries”.
CUBE BIOTECH CEO, Didier Dargent
About Cube Biotech – www.cube-biotech.com – Cube Biotech, headquartered in Monheim, Germany, is a leading provider of solutions for protein purification, stabilization, and structural studies. Known for its high-quality purification resins and membrane protein stabilization kits, Cube Biotech serves researchers across academia and industry. Cube is an ARCHIMED company since 2021.